摘要
白蛋白结合型紫杉醇(NAB-P)为紫杉醇的特殊靶向制剂,其疗效好且不良反应较少。本文主要综述其近两年国内外的临床研究进展。
Nanoparticle albumin - bound paclitaxel（NAB - P）is targeted form of paclitaxel,it has demonstrated clinical benefit in metastatic breast cancer,NSCLC,adenocarcinoma of the pancreas and so on. The advancement of NAB - P in cur-rent clinic researches were reviewed in this article.
出处
《药学研究》
CAS
2014年第5期289-291,共3页
Journal of Pharmaceutical Research
